We treated the genetically matched pair of parental (Vector) cells and the BRCA1-reconstituted HCC1937 breast cancer cells with SAHA44, a broad spectrum HDAC inhibitors and an FDA approved anti-cancer drug (Vorinostat), under normoxia and hypoxia, respectively. This evidence concerns the gene BRCA1 and breast carcinoma.